|
Recently, in a public hospital reform the favorable policy of ice under the influence of pharmaceutical stocks has not only demonstrated their excellent annual performance, while its stock market as a whole is also weakening the case, revealing the self-defensive in nature. The industry believes that the pharmaceutical industry in 2010 sales revenue is expected to maintain a growth rate of over 20% of profits to maintain more than 25% of the growth rate. 2009 is the first year of our new medical reform in 2010, China's pharmaceutical industry will become a new beginning. Annual Performance beautiful stock has the defensive Since January 1, 2010 date, the Shanghai Composite Index fell 337.74 points or 10.31%. In the meantime, the pharmaceutical industry index fell just 43.91 points, or 1.37%. Outperform Shanghai index 9 percentage points. Weak in the overall market performance shown by the case of certain defensive, of course, the pharmaceutical industry itself, which is defensive in nature is all about. For 2009, the pharmaceutical industry's outstanding performance, the industry generally be attributed to the continuity of policies to promote the industry: medical reform draft, the introduction of the program; 850 billion yuan financial investment; Essential Drugs List, the price of the introduction; the introduction of health insurance directory. 2010 Golden State Securities (600,109) that the policy of the opportunity to look forward to: ice-breaking reforms in public hospitals, the new fiscal spending red envelopes issued; around the updated edition of Essential Medicines List; essential drug list rules for the operation and implementation. Increase is driven not only good policy, the original self and its deep-seated reason is the continued growth of the pharmaceutical industry to bring more attractive. 2009 annual reports of listed companies Pharmaceutical beautiful performance. According to statistics, as of February 7, pharmaceutical companies in the notice for the 2009 Yejiyuzeng 36, notice their losses for the 12, notice a slight increase for the 15, notice profitable pharmaceutical companies accounted for 86 of the published results announcement the company's 83.72%. Performance increase of over 50% of the company's announcement pharmaceutical companies accounting for the ratio of 55.81%. Benefit from the policy, the industry pattern of gradual red envelope The reform of public hospitals is a new medical reform in five of the most difficult task of a reform, but also the entire core of the new medical reform involves the interests of the entire pharmaceutical industry, the various chains. From the objectives of the reform of view, on a larger scale of government financial investment is inevitable. One of the tasks of public hospital reform is to remove drug addition, the reform of the hospital compensation mechanism. Addition of part of the hospital medicine, in addition to improving service to rely on other than price, more the need for government subsidies to compensate. China's current annual sales of medicines in public hospitals, an estimated 3,000 billion, 15% of the addition of some 400 billion-plus later, this cancellation may be required to support the Government's investment. This is the Government's financial resources is a test. From the reform trend, the reform of public hospitals to bring change for the pharmaceutical industry, as well as possible investment opportunities. However, given the complexity of the reform of public hospitals, the industry environment in the next three years will become more complex. The long-term interim defensive attack In 2009 a number of medical effects of the policy will be the first from 2010 began to appear in 2010, will also become China's pharmaceutical industry, a new beginning. As the financial crisis is weakening is expected by 2010, the growth rate of China's pharmaceutical industry will be better than this year, 2010, China's pharmaceutical market will reach 200 billion of incremental and full year 2010, gross output value of China's pharmaceutical industry will grow 23%, compared with 3 percentage points higher than in 2009, reaching more than 12.5 thousand billion. Coincides with the industry research institutes is the country that the gold stock in 2010 was the breakthrough year for innovation in the pharmaceutical industry. New drug approval, FDA certification event will occur at every level. Such opportunities may bring related to the valuation of stocks up one level may be high. 2010 may be traditional Chinese medicine injections accelerated industry growth year. Guoxin Securities raised 850 billion of new three-year increment of medical reform highlights the Government's determination to put the next 10 years the pharmaceutical industry golden period of development; medical consumption of drugs has great potential, the market expansion driven by growth in the industry is just beginning; "long-term offensive, defensive phase "is the pharmaceutical industry over the next 10 years, the best investment strategy. I am an expert from diefeiltd.com, while we provides the quality product, such as Pvc Butterfly Valve , Wafer Butterfly Valve, Pvc Butterfly Valve,and more.
Related Articles -
Pvc Butterfly Valve, Wafer Butterfly Valve,
|
